Revolutionizing Medical Technology: Microbot Medical Surpasses $11.8 Million in Fundraising through Direct Offering and Strategic Investments

In a groundbreaking move, Microbot Medical Inc., a pioneering medical technology company based in Hingham, Massachusetts, has successfully raised a total of approximately $11.8 million in gross proceeds. This impressive achievement was made possible through a combination of a registered direct offering and the utilization of an ATM facility.

The registered direct offering, conducted under Nasdaq rules, involved the sale of 4,000,001 shares of Microbot Medical’s common stock at a purchase price of $1.75 per share. Additionally, as part of a concurrent private placement, the company issued unregistered short-term series G preferred investment options allowing for the purchase of up to 8,000,002 shares of common stock at the same price.

H.C. Wainwright & Co., acting as the exclusive placement agent for these offerings, played a pivotal role in facilitating this fundraising initiative. The gross proceeds generated from both the registered direct offering and private placement amounted to approximately $7 million before deducting fees and other expenses.

Furthermore, when combined with funds previously raised through the at-the-market facility – totaling around $4.8 million as of January 2025 – Microbot Medical’s overall gross proceeds reached an impressive sum of $11.8 million. These funds are earmarked for various strategic purposes including continued development and commercialization efforts for the company’s cutting-edge LIBERTY® Robotic System.

Notably, all shares offered by Microbot Medical were done so in compliance with SEC regulations under a “shelf” registration statement on Form S-3 (File No. 333-275634) that was declared effective back in December 2023. The company intends to leverage these funds not only for ongoing product development but also for expanding its intellectual property portfolio and supporting general corporate activities.

Microbot Medical’s vision revolves around enhancing patient care globally by introducing innovative medical technologies such as their single-use endovascular robotic system – designed to overcome traditional barriers to advanced robotic healthcare solutions.

It is

important

to highlight that forward-looking statements made by Microbot Medical Inc., including those related to financial projections and operational milestones, are subject to inherent risks and uncertainties outlined under “Risk Factors” in regulatory filings submitted to the SEC.

By securing substantial funding through strategic initiatives like direct offerings and private placements, Microbot Medical is poised to continue its mission of transforming medical technology landscape while prioritizing innovation and patient-centric care.